Correction to: The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.

MLA

Weerasuriya, Chathika K., et al. “Correction to: The Epidemiologic Impact and Cost-Effectiveness of New Tuberculosis Vaccines on Multidrug-Resistant Tuberculosis in India and China.” BMC Medicine, vol. 20, no. 1, Mar. 2022, p. 99. EBSCOhost, https://doi.org/10.1186/s12916-022-02306-3.

APA

Weerasuriya, C. K., Harris, R. C., McQuaid, C. F., Bozzani, F., Ruan, Y., Li, R., Li, T., Rade, K., Rao, R., Ginsberg, A. M., Gomez, G. B., & White, R. G. (2022). Correction to: The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China. BMC Medicine, 20(1), 99. https://doi.org/10.1186/s12916-022-02306-3

Chicago

Weerasuriya, Chathika K, Rebecca C Harris, C Finn McQuaid, Fiammetta Bozzani, Yunzhou Ruan, Renzhong Li, Tao Li, et al. 2022. “Correction to: The Epidemiologic Impact and Cost-Effectiveness of New Tuberculosis Vaccines on Multidrug-Resistant Tuberculosis in India and China.” BMC Medicine 20 (1): 99. doi:10.1186/s12916-022-02306-3.